On September 12, 2016 the biotech company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) reported first preliminary data on its EnanDIM technology in a murine tumor model. EnanDIM is a new family of TLR9 agonists and so-called Immune Surveillance Reactivators (ISR) (Press release, Mologen, SEP 12, 2016, View Source [SID:SID1234515097]). The pre-clinical in vivo data shows that EnanDIM can reduce tumor growth and thus prolong survival. It has been shown previously that EnanDIM molecules broadly activate immune cells in vitro and revealed no signs of toxicity after the administration of maximal feasible doses in vivo. These data constitute the next pre-clinical step towards a clinical development program of EnanDIM in the treatment of cancer. Schedule your 30 min Free 1stOncology Demo! "This is the next important step for our promising new generation TLR9 agonist EnanDIM. For the first time we observed reduced tumor growth in a murine model. These results strongly support the pre-clinical development of our EnanDIM compounds", said Dr Mariola Söhngen, CEO of MOLOGEN AG.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
MOLOGEN’s new strategy program "Next Level", presented beginning of June 2016, includes a clear concentration on the lead product, the cancer immunotherapy lefitolimod and next-generation molecules EnanDIM.
EnanDIM (Enantiomeric, DNA-based, ImmunoModulator), as a new generation of immunomodulators and so-called Immune Surveillance Reactivators (ISR), belongs to the class of TLR9 agonists and represents one of MOLOGEN’s follow-up compounds to lefitolimod (MGN1703) exhibiting longer patent protection, and a one-step production process as well as an immunomodulatory pattern dependent on the specific EnanDIM molecule.
The EnanDIM molecules consist entirely of natural DNA, as is also the case with lefitolimod (MGN1703). The main difference between MOLOGEN’s two ISR families is their molecule structure. Whereas lefitolimod (MGN1703) is dumbbell-shaped and covalently-closed, EnanDIM molecules have a linear structure. However, as with lefitolimod (MGN1703), due to its specific structure, no chemical modification is needed in order to protect the molecules against degradation by enzymes.
The EnanDIM ISR promise a broad activation of the immune system with a good safety and tolerability profile. Due to their characteristic mechanism of action, EnanDIM molecules have the potential to be applied in various cancer indications. Additionally, it may be possible to develop selected members of the EnanDIM family both for monotherapy and in combination with targeted forms of treatment, such as checkpoint inhibitors and other immunotherapeutic approaches. Moreover, different members of the EnanDIM family may also be used in the area of infectious diseases – including HIV.
The data will be presented at the Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (CIMT) (Free CIMT Whitepaper) in New York, USA (September 25-28, 2016). The conference will be organized by the Cancer Research Institute (CRI), die Association for Cancer lmmunotherapy (CIMT) (Free CIMT Whitepaper), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR) (Free AACR Whitepaper).
Abstract details:
Abstract number: # 278
Title: "Preclinical data of novel enantiomeric oligonucleotides for cancer immunotherapy: The TLR9 agonist EnanDIM"
Poster presentation: September 26, from 5:15-7:45 pm
Poster Number: B067
For more information on the Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (CIMT) (Free CIMT Whitepaper) please visit the website: www.aacr.org.
About EnanDIM
EnanDIM (Enantiomeric, DNA-based, ImmunoModulator) is an innovative linear DNA-based TLR9 agonist in pre-clinical development. It broadly and strongly activates the immune system. EnanDIM could be used in various cancer indications either as monotherapy, in combination with other targeted therapies or immune modulators, such as so called checkpoint inhibitors, or with other immunotherapeutic approaches. It could also potentially be used in the field of infectious diseases.